- Home
- KBR vs NUVL Comparison
KBR vs NUVL Comparison
Compare KBR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- NUVL
- Stock Information
- Founded
- KBR 1901
- NUVL 2017
- Country
- KBR United States
- NUVL United States
- Employees
- KBR N/A
- NUVL N/A
- Industry
- KBR Military/Government/Technical
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- NUVL Health Care
- Exchange
- KBR Nasdaq
- NUVL Nasdaq
- Market Cap
- KBR 6.3B
- NUVL 5.6B
- IPO Year
- KBR 2006
- NUVL 2021
- Fundamental
- Price
- KBR $50.51
- NUVL $71.64
- Analyst Decision
- KBR Strong Buy
- NUVL Strong Buy
- Analyst Count
- KBR 8
- NUVL 9
- Target Price
- KBR $71.13
- NUVL $113.44
- AVG Volume (30 Days)
- KBR 1.4M
- NUVL 703.3K
- Earning Date
- KBR 05-06-2025
- NUVL 05-08-2025
- Dividend Yield
- KBR 1.31%
- NUVL N/A
- EPS Growth
- KBR N/A
- NUVL N/A
- EPS
- KBR 2.79
- NUVL N/A
- Revenue
- KBR $7,742,000,000.00
- NUVL N/A
- Revenue This Year
- KBR $15.82
- NUVL N/A
- Revenue Next Year
- KBR $9.28
- NUVL N/A
- P/E Ratio
- KBR $18.10
- NUVL N/A
- Revenue Growth
- KBR 11.30
- NUVL N/A
- 52 Week Low
- KBR $43.89
- NUVL $55.54
- 52 Week High
- KBR $72.60
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- KBR 50.87
- NUVL 52.01
- Support Level
- KBR $49.67
- NUVL $55.54
- Resistance Level
- KBR $51.01
- NUVL $68.45
- Average True Range (ATR)
- KBR 2.17
- NUVL 5.47
- MACD
- KBR 0.18
- NUVL 0.75
- Stochastic Oscillator
- KBR 66.20
- NUVL 93.01
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.